ezetimibe has been researched along with eicosapentaenoic acid in 11 studies
| Studies (ezetimibe) | Trials (ezetimibe) | Recent Studies (post-2010) (ezetimibe) | Studies (eicosapentaenoic acid) | Trials (eicosapentaenoic acid) | Recent Studies (post-2010) (eicosapentaenoic acid) |
|---|---|---|---|---|---|
| 2,484 | 563 | 1,465 | 7,171 | 1,304 | 3,623 |
| Protein | Taxonomy | ezetimibe (IC50) | eicosapentaenoic acid (IC50) |
|---|---|---|---|
| Chain A, Protein (peroxisome Proliferator Activated Receptor (ppar-delta)) | Homo sapiens (human) | 4 | |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 7.1 | |
| Oxoeicosanoid receptor 1 | Homo sapiens (human) | 2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 5 (45.45) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ito, H; Kimura, T; Kohno, K; Kubo, M; Miyoshi, T; Morita, H; Nakamura, K; Noda, Y | 1 |
| Castaldo, RS | 1 |
| Habe, K; Higashiyama, A; Mizutani, H; Omoto, Y; Yamanaka, K; Yokoyama, T | 1 |
| Barrett, PH; Burnett, JR; Chan, DC; Mori, TA; Pang, J; Sullivan, DR; van Bockxmeer, FM; Watts, GF | 1 |
| Arashi, H; Hagiwara, N; Haruta, S; Ishii, Y; Kawada-Watanabe, E; Koyanagi, R; Mori, F; Murasaki, S; Ogawa, H; Sekiguchi, H; Suzuki, K; Yamaguchi, J; Yamauchi, T | 1 |
| Angiolillo, DJ; Cao, D; Claessen, BE; Gibson, CM; Guedeney, P; Lepor, N; Mehran, R | 1 |
| Anderson, TJ; Barry, AR; Couture, P; Dayan, N; Francis, GA; Genest, J; Grégoire, J; Grover, SA; Gupta, M; Hegele, RA; Lau, D; Leiter, LA; Leung, AA; Lonn, E; Mancini, GBJ; Manjoo, P; McPherson, R; Ngui, D; Pearson, GJ; Piché, ME; Poirier, P; Sievenpiper, J; Stone, J; Thanassoulis, G; Ward, R; Wray, W | 1 |
| Lloyd-Jones, DM; Wilkins, JT | 1 |
| Boch, T; Michaeli, DT; Michaeli, JC; Michaeli, T | 1 |
| Di Costanzo, A; Esposito, G; Indolfi, C; Sorrentino, S; Spaccarotella, CAM | 1 |
2 review(s) available for ezetimibe and eicosapentaenoic acid
| Article | Year |
|---|---|
Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cholesterol, LDL; Cost-Benefit Analysis; Dicarboxylic Acids; Eicosapentaenoic Acid; Ezetimibe; Fatty Acids; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Male; Middle Aged; Myocardial Ischemia; PCSK9 Inhibitors; Practice Guidelines as Topic; Risk Reduction Behavior; RNA, Small Interfering; Secondary Prevention | 2020 |
The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function.
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Eicosapentaenoic Acid; Ezetimibe; Fibrinolytic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; PCSK9 Inhibitors; Proprotein Convertase 9; Triglycerides | 2023 |
3 trial(s) available for ezetimibe and eicosapentaenoic acid
| Article | Year |
|---|---|
Add-on ezetimibe reduces small dense low-density lipoprotein cholesterol levels without affecting absorption of eicosapentaenoic acid in patients with coronary artery disease: a pilot study.
Topics: Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Drug Therapy, Combination; Eicosapentaenoic Acid; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intestinal Absorption; Male; Pilot Projects; Prospective Studies | 2014 |
Effect of omega-3 fatty acid supplementation on arterial elasticity in patients with familial hypercholesterolaemia on statin therapy.
Topics: Apolipoprotein B-100; Arterial Pressure; Biomarkers; Cardiovascular Diseases; Cross-Over Studies; Dietary Supplements; Docosahexaenoic Acids; Drug Combinations; Eicosapentaenoic Acid; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Time Factors; Treatment Outcome; Triglycerides; Vascular Stiffness; Western Australia | 2016 |
Polyunsaturated Fatty Acid Impact on Clinical Outcomes in Acute Coronary Syndrome Patients With Dyslipidemia: Subanalysis of HIJ-PROPER.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Anticholesteremic Agents; Arachidonic Acid; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Eicosapentaenoic Acid; Ezetimibe; Fatty Acids, Unsaturated; Female; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Prognosis; Quinolines; Risk Assessment; Stroke | 2019 |
6 other study(ies) available for ezetimibe and eicosapentaenoic acid
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A retrospective case series of the lipid effects of switching from omega-3 fatty acid ethyl esters to icosapent ethyl in hyperlipidemic patients.
Topics: Aged; Azetidines; Eicosapentaenoic Acid; Esters; Ezetimibe; Fatty Acids, Omega-3; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Lipids; Male; Middle Aged; New York; Random Allocation; Retrospective Studies | 2014 |
Flutamide-induced photoleukomelanoderma.
Topics: Administration, Cutaneous; Aged; Androgen Antagonists; Benzimidazoles; Biopsy; Biphenyl Compounds; Bisoprolol; Clopidogrel; Drug Eruptions; Eicosapentaenoic Acid; Ezetimibe; Flutamide; Glucocorticoids; Humans; Male; Patch Tests; Photosensitivity Disorders; Prostatic Neoplasms; Skin Pigmentation; Sunlight; Tetrazoles; Ticlopidine; Ursodeoxycholic Acid; Withholding Treatment | 2016 |
2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults.
Topics: Adult; Apolipoproteins B; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Dietary Supplements; Dyslipidemias; Eicosapentaenoic Acid; Ezetimibe; Female; Health Behavior; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Pregnancy; Pregnancy Complications; Primary Prevention; Risk Assessment; Secondary Prevention | 2021 |
Novel Lipid-Lowering Therapies to Reduce Cardiovascular Risk.
Topics: Cardiovascular Diseases; Dicarboxylic Acids; Eicosapentaenoic Acid; Ezetimibe; Fatty Acids; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; PCSK9 Inhibitors; RNA, Small Interfering | 2021 |
Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy.
Topics: Antibodies, Monoclonal, Humanized; Cardiovascular Diseases; Cost-Benefit Analysis; Dyslipidemias; Eicosapentaenoic Acid; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Proprotein Convertase 9; Quality-Adjusted Life Years; State Medicine | 2022 |